Local salvage therapy for late (≥2 years) metastatic and local relapse of renal cell cancer is a potentially curative treatment irrespective of the site of recurrence

Objective - The primary treatment approach to locoregional renal cell carcinoma (RCC) is surgical resection. Most relapses occur within the first 2 years but some patients experience late recurrences. Surgical resection of oligometastatic disease may be considered a curative option for relapsed RCC....

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Grüllich, Carsten (VerfasserIn) , Vallet, Sonia (VerfasserIn) , Hecht, Christopher (VerfasserIn) , Duensing, Stefan (VerfasserIn) , Hadaschik, Boris (VerfasserIn) , Jäger, Dirk (VerfasserIn) , Hohenfellner, Markus (VerfasserIn) , Pahernik, Sascha (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 2016
In: Urologic oncology
Year: 2015, Jahrgang: 34, Heft: 5, Pages: 238.e9-238.e17
ISSN:1873-2496
DOI:10.1016/j.urolonc.2015.11.022
Online-Zugang:Verlag, Volltext: https://doi.org/10.1016/j.urolonc.2015.11.022
Verlag, Volltext: http://www.sciencedirect.com/science/article/pii/S1078143915005748
Volltext
Verfasserangaben:Carsten Grüllich, M.D., Sonia Vallet, M.D., Christopher Hecht, Stephan Duensing, M.D., Ph.D., Boris Hadaschik, M.D., Dirk Jäger, M.D., Markus Hohenfellner, M.D., Sascha Pahernik, M.D.

MARC

LEADER 00000caa a2200000 c 4500
001 1680553372
003 DE-627
005 20230426084735.0
007 cr uuu---uuuuu
008 191029r20162015xx |||||o 00| ||eng c
024 7 |a 10.1016/j.urolonc.2015.11.022  |2 doi 
035 |a (DE-627)1680553372 
035 |a (DE-599)KXP1680553372 
035 |a (OCoLC)1341249502 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Grüllich, Carsten  |d 1965-  |e VerfasserIn  |0 (DE-588)14101914X  |0 (DE-627)624500985  |0 (DE-576)321797981  |4 aut 
245 1 0 |a Local salvage therapy for late (≥2 years) metastatic and local relapse of renal cell cancer is a potentially curative treatment irrespective of the site of recurrence  |c Carsten Grüllich, M.D., Sonia Vallet, M.D., Christopher Hecht, Stephan Duensing, M.D., Ph.D., Boris Hadaschik, M.D., Dirk Jäger, M.D., Markus Hohenfellner, M.D., Sascha Pahernik, M.D. 
264 1 |c 2016 
300 |a 9 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Available online 28 December 2015 
500 |a Gesehen am 29.10.2019 
520 |a Objective - The primary treatment approach to locoregional renal cell carcinoma (RCC) is surgical resection. Most relapses occur within the first 2 years but some patients experience late recurrences. Surgical resection of oligometastatic disease may be considered a curative option for relapsed RCC. However, limited data are available of long-term follow-up of late relapse regarding treatment choice. - Patients and methods - We identified 104 patients with RCC from our database, who relapsed after≥2 years from resection of their primary tumor. Median age at primary diagnosis was 61 years and sex distribution was F:M = 40:64. Histology was clear cell, n = 103 and papillary, n = 1. Sites of relapse were local, n = 14 (13.4%); lung only, n = 25 (24.0%); or extrapulmonary, n = 65 (62.5%). Treatment at first relapse was local therapy (LT) in n = 60 (57.7%) patients, of these, n = 55 patients had surgery done and n = 5 patients had underwent radiotherapy. Systemic therapy was used in n = 9 (8.7%) patients. Overall, 35 patients received best supportive care (33.7%). - Results - We found a median overall survival (OS) of 49.8 months (95% CI: 29.3-70.2) and a progression-free survival (PFS) of 21.6 months (95% CI: 12.6-30.5) for all patients. Patients receiving LT had a median OS of 99.9 months (95% CI: 77.2-122.6) and a PFS of 31.1 months (95% CI: 21.5-40.7). Patients treated with systemic therapy, in turn, had an OS of 21.1 months (95% CI: 8.4-33.8) and a PFS of 4 months (95% CI: 1.0-6.2). Patients who received best supportive care had an OS of 10 months (95% CI: 1.3-18.7). This difference was highly significant (log rank for PFS: P<0.001; log rank for OS: P<0.003). Subgroup analysis of the LT group showed a superior outcome for local relapses (OS: not reached, PFS: 61.4mo [95% CI: 28.5-9.2]) compared to visceral relapses (OS: 35.5mo [95% CI: 17.9-53.1], PFS: 21.1mo [95% CI: 19.2-22.9]). - Conclusion - Local salvage therapy should be considered the first therapeutic option in late relapse of RCC irrespective of the site of relapse. 
534 |c 2015 
650 4 |a Late relapse 
650 4 |a Local salvage 
650 4 |a Renal cell cancer 
700 1 |a Vallet, Sonia  |d 1976-  |e VerfasserIn  |0 (DE-588)105867207X  |0 (DE-627)797396403  |0 (DE-576)414826493  |4 aut 
700 1 |a Hecht, Christopher  |d 1983-  |e VerfasserIn  |0 (DE-588)1129481395  |0 (DE-627)884086577  |0 (DE-576)48643043X  |4 aut 
700 1 |a Duensing, Stefan  |d 1967-  |e VerfasserIn  |0 (DE-588)1074044487  |0 (DE-627)830213007  |0 (DE-576)435550098  |4 aut 
700 1 |a Hadaschik, Boris  |d 1974-  |e VerfasserIn  |0 (DE-588)124300553  |0 (DE-627)085770930  |0 (DE-576)294109013  |4 aut 
700 1 |a Jäger, Dirk  |d 1964-  |e VerfasserIn  |0 (DE-588)1032507535  |0 (DE-627)738505323  |0 (DE-576)380074125  |4 aut 
700 1 |a Hohenfellner, Markus  |d 1958-  |e VerfasserIn  |0 (DE-588)133862518  |0 (DE-627)557857988  |0 (DE-576)300155263  |4 aut 
700 1 |a Pahernik, Sascha  |d 1968-  |e VerfasserIn  |0 (DE-588)122063163  |0 (DE-627)081713495  |0 (DE-576)293073147  |4 aut 
773 0 8 |i Enthalten in  |t Urologic oncology  |d Amsterdam [u.a.] : Elsevier Science, 1995  |g 34(2016), 5, Seite 238.e9-238.e17  |h Online-Ressource  |w (DE-627)320491021  |w (DE-600)2011021-2  |w (DE-576)272349585  |x 1873-2496  |7 nnas  |a Local salvage therapy for late (≥2 years) metastatic and local relapse of renal cell cancer is a potentially curative treatment irrespective of the site of recurrence 
773 1 8 |g volume:34  |g year:2016  |g number:5  |g pages:238.e9-238.e17  |g extent:9  |a Local salvage therapy for late (≥2 years) metastatic and local relapse of renal cell cancer is a potentially curative treatment irrespective of the site of recurrence 
856 4 0 |u https://doi.org/10.1016/j.urolonc.2015.11.022  |x Verlag  |x Resolving-System  |3 Volltext 
856 4 0 |u http://www.sciencedirect.com/science/article/pii/S1078143915005748  |x Verlag  |3 Volltext 
951 |a AR 
992 |a 20191029 
993 |a Article 
994 |a 2016 
998 |g 122063163  |a Pahernik, Sascha  |m 122063163:Pahernik, Sascha  |d 910000  |d 910200  |e 910000PP122063163  |e 910200PP122063163  |k 0/910000/  |k 1/910000/910200/  |p 8  |y j 
998 |g 133862518  |a Hohenfellner, Markus  |m 133862518:Hohenfellner, Markus  |d 910000  |d 910200  |e 910000PH133862518  |e 910200PH133862518  |k 0/910000/  |k 1/910000/910200/  |p 7 
998 |g 1032507535  |a Jäger, Dirk  |m 1032507535:Jäger, Dirk  |d 910000  |e 910000PJ1032507535  |k 0/910000/  |p 6 
998 |g 124300553  |a Hadaschik, Boris  |m 124300553:Hadaschik, Boris  |d 910000  |d 910200  |e 910000PH124300553  |e 910200PH124300553  |k 0/910000/  |k 1/910000/910200/  |p 5 
998 |g 1074044487  |a Duensing, Stefan  |m 1074044487:Duensing, Stefan  |d 910000  |d 910200  |e 910000PD1074044487  |e 910200PD1074044487  |k 0/910000/  |k 1/910000/910200/  |p 4 
998 |g 1129481395  |a Hecht, Christopher  |m 1129481395:Hecht, Christopher  |d 910000  |d 910200  |e 910000PH1129481395  |e 910200PH1129481395  |k 0/910000/  |k 1/910000/910200/  |p 3 
998 |g 105867207X  |a Vallet, Sonia  |m 105867207X:Vallet, Sonia  |d 910000  |e 910000PV105867207X  |k 0/910000/  |p 2 
998 |g 14101914X  |a Grüllich, Carsten  |m 14101914X:Grüllich, Carsten  |d 910000  |e 910000PG14101914X  |k 0/910000/  |p 1  |x j 
999 |a KXP-PPN1680553372  |e 3530836060 
BIB |a Y 
SER |a journal 
JSO |a {"id":{"doi":["10.1016/j.urolonc.2015.11.022"],"eki":["1680553372"]},"physDesc":[{"extent":"9 S."}],"title":[{"title":"Local salvage therapy for late (≥2 years) metastatic and local relapse of renal cell cancer is a potentially curative treatment irrespective of the site of recurrence","title_sort":"Local salvage therapy for late (≥2 years) metastatic and local relapse of renal cell cancer is a potentially curative treatment irrespective of the site of recurrence"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"origin":[{"dateIssuedDisp":"2016","dateIssuedKey":"2016"}],"relHost":[{"part":{"text":"34(2016), 5, Seite 238.e9-238.e17","issue":"5","extent":"9","pages":"238.e9-238.e17","volume":"34","year":"2016"},"language":["eng"],"note":["Gesehen am 22.11.04"],"pubHistory":["1.1995 -"],"disp":"Local salvage therapy for late (≥2 years) metastatic and local relapse of renal cell cancer is a potentially curative treatment irrespective of the site of recurrenceUrologic oncology","type":{"media":"Online-Ressource","bibl":"periodical"},"recId":"320491021","physDesc":[{"extent":"Online-Ressource"}],"id":{"issn":["1873-2496"],"eki":["320491021"],"zdb":["2011021-2"]},"title":[{"title":"Urologic oncology","title_sort":"Urologic oncology"}],"origin":[{"dateIssuedDisp":"1995-","publisher":"Elsevier Science","publisherPlace":"Amsterdam [u.a.]","dateIssuedKey":"1995"}]}],"language":["eng"],"name":{"displayForm":["Carsten Grüllich, M.D., Sonia Vallet, M.D., Christopher Hecht, Stephan Duensing, M.D., Ph.D., Boris Hadaschik, M.D., Dirk Jäger, M.D., Markus Hohenfellner, M.D., Sascha Pahernik, M.D."]},"note":["Available online 28 December 2015","Gesehen am 29.10.2019"],"person":[{"role":"aut","family":"Grüllich","given":"Carsten","display":"Grüllich, Carsten"},{"given":"Sonia","display":"Vallet, Sonia","role":"aut","family":"Vallet"},{"family":"Hecht","role":"aut","display":"Hecht, Christopher","given":"Christopher"},{"family":"Duensing","role":"aut","display":"Duensing, Stefan","given":"Stefan"},{"given":"Boris","display":"Hadaschik, Boris","role":"aut","family":"Hadaschik"},{"display":"Jäger, Dirk","given":"Dirk","family":"Jäger","role":"aut"},{"given":"Markus","display":"Hohenfellner, Markus","family":"Hohenfellner","role":"aut"},{"family":"Pahernik","role":"aut","given":"Sascha","display":"Pahernik, Sascha"}],"recId":"1680553372"} 
SRT |a GRUELLICHCLOCALSALVA2016